ES8606398A1 - Procedimiento para la obtencion de lipopeptidos - Google Patents

Procedimiento para la obtencion de lipopeptidos

Info

Publication number
ES8606398A1
ES8606398A1 ES529091A ES529091A ES8606398A1 ES 8606398 A1 ES8606398 A1 ES 8606398A1 ES 529091 A ES529091 A ES 529091A ES 529091 A ES529091 A ES 529091A ES 8606398 A1 ES8606398 A1 ES 8606398A1
Authority
ES
Spain
Prior art keywords
amino
alpha
acids
radical
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES529091A
Other languages
English (en)
Other versions
ES529091A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES529091A0 publication Critical patent/ES529091A0/es
Publication of ES8606398A1 publication Critical patent/ES8606398A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PROCEDIMIENTO PARA LA OBTENCION DE LIPOPEPTIDOS. CONSISTE EN ESTABLECER UN ENLACE AMIDA EN UN COMPUESTO DE FORMULA (I) CON UN GRUPO CARBOXILO LIBRE, EN UN DISOLVENTE INERTE COMO DIMETILFORMAMIDA DIMETILACETAMIDA, CLOROFORMO, CLORURO DE METILENO O ACETONITRILO ENTRE 20 Y 120JC, PARA OBTENER EL LIPOPEPTIDO DESEADO. SIENDO: R1A Y R1B, INDEPENDIENTES ENTRE SI, RESTO HIDROCARBURO ALIFATICO O ALIFATICO-CICLOALIFATICO DE C 1 A 21; AS0, RESTO -O-KW-CO- O -NH-KW-CO-; KW, RESTO HIDROCARBURO ALIFATICO DE C 1 A 12; AS1, UN D- O L-A-AMINOACIDO; Z1 Y Z2, INDEPENDIENTEMENTE, HIDROXI O EL RESTO N-TERMINAL DE UN ACIDO D- O L-A-AMINO-CARBOXILICO; Z3, H O -CO-Z4; Z4, COMO Z1; Y R O S, CENTROS DE ASIMETRIA. SE UTILIZA COMO POTENCIADOR DE LAS REACCIONES INMUNOLOGICAS.
ES529091A 1983-01-25 1984-01-23 Procedimiento para la obtencion de lipopeptidos Expired ES8606398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH39883 1983-01-25

Publications (2)

Publication Number Publication Date
ES529091A0 ES529091A0 (es) 1986-04-01
ES8606398A1 true ES8606398A1 (es) 1986-04-01

Family

ID=4186110

Family Applications (3)

Application Number Title Priority Date Filing Date
ES529091A Expired ES8606398A1 (es) 1983-01-25 1984-01-23 Procedimiento para la obtencion de lipopeptidos
ES544194A Expired ES8606393A1 (es) 1983-01-25 1985-06-14 Procedimiento para la obtencion de lipopeptidos
ES544193A Expired ES8802620A1 (es) 1983-01-25 1985-06-14 Procedimiento para la obtencion de lipopeptidos

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES544194A Expired ES8606393A1 (es) 1983-01-25 1985-06-14 Procedimiento para la obtencion de lipopeptidos
ES544193A Expired ES8802620A1 (es) 1983-01-25 1985-06-14 Procedimiento para la obtencion de lipopeptidos

Country Status (18)

Country Link
US (1) US4666886A (es)
EP (1) EP0114787B1 (es)
JP (1) JPH068316B2 (es)
AT (1) ATE67769T1 (es)
AU (1) AU569865B2 (es)
CA (1) CA1247089A (es)
DD (1) DD213917A5 (es)
DE (1) DE3485094D1 (es)
DK (1) DK31684A (es)
ES (3) ES8606398A1 (es)
FI (1) FI83524C (es)
GR (1) GR81710B (es)
HU (1) HU192864B (es)
IE (1) IE57092B1 (es)
IL (1) IL70766A (es)
NZ (1) NZ206923A (es)
PT (1) PT78002B (es)
ZA (1) ZA84521B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986004334A1 (en) * 1985-01-18 1986-07-31 MERCK Patent Gesellschaft mit beschränkter Haftung Immunoregulatory peptides
DE3546150A1 (de) 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
US6074650A (en) * 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US6024964A (en) * 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
DE3522638A1 (de) * 1985-06-25 1987-01-08 Diamalt Ag Neue somatostatin-derivate
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US5374426A (en) * 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
CA1315465C (en) * 1987-07-31 1993-03-30 Hans-Helmut Goertz Polymers of oxyalkylated unsaturated quaternary ammonium salts, their preparation and their use
JPH0832638B2 (ja) * 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
DE4119856A1 (de) * 1991-06-17 1992-12-24 Hoechst Ag N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
ES2096064T3 (es) * 1991-12-19 1997-03-01 Ciba Geigy Ag Derivados del acido aminosulfonico y procedimiento para su obtencion.
EP0604945A1 (en) * 1992-12-28 1994-07-06 Takeda Chemical Industries, Ltd. TAN-1511, its derivatives, production and use thereof
AU666789B2 (en) * 1992-12-28 1996-02-22 Takeda Chemical Industries Ltd. 2-amino-6,7-dihydroxy-4-thiaheptanoic acid derivatives, production and use thereof
EP0641776A3 (en) * 1993-09-08 1997-05-02 Takeda Chemical Industries Ltd Thioglycerol derivatives.
WO1996040213A1 (en) * 1995-06-07 1996-12-19 Cytel Corporation Manufacture and purification of peptides
EP1018877A4 (en) * 1995-10-17 2000-08-09 Dovetail Technologies Inc LOW MOLECULAR WEIGHT STIMULANTS OF BONE MARROW AND IMMUNE SYSTEM CELLS
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
PT921125E (pt) * 1997-12-05 2002-06-28 Hoffmann La Roche Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
GB0016811D0 (en) * 2000-07-07 2000-08-30 Adprotech Ltd Lipid rafts
FR2816060A1 (fr) * 2000-10-27 2002-05-03 Pf Medicament Procede d'identification de nouvelles molecules se liant au recepteur lox et utilisation de ces molecules
EP2189473A3 (en) * 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Nucleic and proteins from streptococcus groups A & B
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
AU2006272647A1 (en) * 2005-07-25 2007-02-01 Therimunex Pharmaceuticals, Inc. Peptidyl diacylglycerides
US8299129B2 (en) 2006-03-01 2012-10-30 Fukuoka Prefectural Government Peptide lipid-containing carrier and method for introducing compound into cells using same
US20080051603A1 (en) * 2006-06-15 2008-02-28 Cell Therapeutics, Inc. Process for the preparation of poly-alpha-glutamic acid and derivatives thereof
KR101730351B1 (ko) 2009-03-25 2017-04-28 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 병원체에 대한 포유동물의 선천성 면역 저항성의 자극을 위한 조성물
KR101080271B1 (ko) * 2009-03-31 2011-11-08 주식회사 웰스킨 다이펩타이드를 유효성분으로 포함하는 자외선에 의한 홍반반응 억제용 화장품 조성물
CA2766907A1 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
WO2011008974A2 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
DE102009034779A1 (de) * 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
MX2012002723A (es) 2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
WO2011119759A1 (en) * 2010-03-23 2011-09-29 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
JP2013533745A (ja) 2010-07-06 2013-08-29 ノバルティス アーゲー ノロウイルスに由来する免疫原性組成物および方法
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012031140A1 (en) 2010-09-01 2012-03-08 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
EP2667892B1 (en) 2011-01-26 2019-03-27 GlaxoSmithKline Biologicals SA Rsv immunization regimen
EP2680885B8 (en) 2011-03-02 2018-07-25 GlaxoSmithKline Biologicals SA Combination vaccines with lower doses of antigen and/or adjuvant
EP2688590B1 (en) * 2011-03-24 2020-02-12 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with phospholipids
LT3275892T (lt) 2011-05-13 2020-04-10 Glaxosmithkline Biologicals S.A. Struktūros prieš suliejimą rsv f antigenai
US20140363461A1 (en) 2011-09-01 2014-12-11 Fabio Bagnoli Adjuvanted formulations of staphylococcus aureus antigens
NL2007536C2 (en) * 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
US20150030630A1 (en) 2012-03-07 2015-01-29 Novartis Ag Adjuvanted formulations of rabies virus immunogens
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
EP2822581A2 (en) 2012-03-08 2015-01-14 Novartis AG Adjuvanted formulations of dtp booster vaccines
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
CA2882619A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
CA2886938A1 (en) 2012-10-12 2014-04-17 Glaxosmithkline Biologicals S.A. Non-cross-linked acellular pertussis antigens for use in combination vaccines
ES2670863T3 (es) 2013-02-01 2018-06-01 Glaxosmithkline Biologicals Sa Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll
US20140335116A1 (en) 2013-05-10 2014-11-13 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
AU2015238512B2 (en) 2014-03-26 2018-02-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
AU2016271857B2 (en) 2015-06-03 2020-05-28 Affiris Ag IL-23-P19 vaccines
WO2017005851A1 (en) 2015-07-07 2017-01-12 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
DE102016005550B4 (de) 2016-05-09 2024-09-26 Hans-Georg Rammensee Adjuvans zur lnduzierung einer zellulären lmmunantwort
WO2018183827A1 (en) * 2017-03-31 2018-10-04 Temple University-Of The Commonwealth System Of Higher Education Flexible variable differential transformer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000330B1 (de) * 1977-06-20 1981-08-05 Ciba-Geigy Ag Lipopeptide, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Präparate
HU186585B (en) * 1978-05-18 1985-08-28 Ciba Geigy Ag Process for producing new muramil-peptide derivatives
EP0014815A3 (de) * 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
FR2460290A1 (fr) * 1979-06-29 1981-01-23 Rhone Poulenc Ind Nouveaux tetra- ou pentapeptides, leur preparation et les medicaments qui les contiennent
FR2460288A1 (fr) * 1979-06-29 1981-01-23 Rhone Poulenc Ind Nouveaux dipeptides, leur preparation et les medicaments qui les contiennent

Also Published As

Publication number Publication date
FI840259A (fi) 1984-07-26
EP0114787B1 (de) 1991-09-25
ES8606393A1 (es) 1986-04-01
ES8802620A1 (es) 1988-09-16
EP0114787A3 (en) 1987-05-06
AU569865B2 (en) 1988-02-25
IE57092B1 (en) 1992-04-22
GR81710B (es) 1984-12-12
JPS59139348A (ja) 1984-08-10
ES544193A0 (es) 1988-09-16
ZA84521B (en) 1984-09-26
ES544194A0 (es) 1986-04-01
CA1247089A (en) 1988-12-20
AU2374584A (en) 1984-07-26
DD213917A5 (de) 1984-09-26
DK31684D0 (da) 1984-01-24
DE3485094D1 (de) 1991-10-31
DK31684A (da) 1984-07-26
FI83524C (fi) 1991-07-25
HU192864B (en) 1987-07-28
PT78002A (en) 1984-02-01
NZ206923A (en) 1988-05-30
US4666886A (en) 1987-05-19
EP0114787A2 (de) 1984-08-01
PT78002B (en) 1986-06-18
IL70766A0 (en) 1984-04-30
ES529091A0 (es) 1986-04-01
IL70766A (en) 1987-08-31
IE840157L (en) 1984-07-25
JPH068316B2 (ja) 1994-02-02
FI83524B (fi) 1991-04-15
FI840259A0 (fi) 1984-01-23
ATE67769T1 (de) 1991-10-15

Similar Documents

Publication Publication Date Title
ES8606393A1 (es) Procedimiento para la obtencion de lipopeptidos
ES8606394A1 (es) Procedimiento para la obtencion de tetrapeptidos sustituidos
ES478717A1 (es) Procedimiento para la obtencion de lipopetidos.
IE812974L (en) Tri-,tetra- and penta peptides
AU582772B2 (en) Phosphatidyl compounds, processes for their manufacture, and their use
ES471696A1 (es) Procedimiento para la obtencion de nuevos derivados de 3- -oxaloamino-4-oxo-4h-1-benzopirano
AU2272988A (en) Zinc salts, lead salts and/or calcium salts of carboxylic acids and their use as corrosion inhibitors
GB1178329A (en) N-[delta-(6-Purinylthio) Valeryl] Amino Acids and derivatives thereof, and a method of producing the same
ES557261A1 (es) Procedimiento para la obtencion de azacicloalcanos y azacicloalquenos 1,3,4-trisustituidos
ES8800924A1 (es) Procedimiento para la obtencion de benzotiopiranonas
ES8301989A1 (es) Procedimiento para la obtencion de amidinas de acido carbo- xilico n,n'-puenteadas
MX9700929A (es) Metodos y composiciones utiles en la profilaxis y terapia de condiciones relacionadas a la endotoxina.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970612